Evolent Health FY2024 EPS Estimate Boosted by William Blair

Evolent Health, Inc. (NYSE:EVH) – William Blair lifted their FY2024 earnings per share estimates for shares of Evolent Health in a report issued on Monday, January 13th. William Blair analyst R. Daniels now anticipates that the technology company will post earnings per share of $0.23 for the year, up from their previous forecast of $0.19. The consensus estimate for Evolent Health’s current full-year earnings is $0.24 per share. William Blair also issued estimates for Evolent Health’s Q4 2024 earnings at ($0.05) EPS and FY2025 earnings at $0.48 EPS.

EVH has been the topic of several other reports. KeyCorp initiated coverage on Evolent Health in a report on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective on the stock. Citigroup reduced their price objective on Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, January 10th. JPMorgan Chase & Co. reduced their price target on Evolent Health from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, November 22nd. Needham & Company LLC began coverage on Evolent Health in a research report on Friday, January 10th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Truist Financial reduced their price target on Evolent Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Monday. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $21.92.

Evolent Health Trading Up 2.1 %

EVH opened at $10.18 on Thursday. The stock’s fifty day moving average is $12.15 and its two-hundred day moving average is $20.84. The company has a market capitalization of $1.19 billion, a P/E ratio of -11.18 and a beta of 1.45. Evolent Health has a 52 week low of $9.88 and a 52 week high of $35.00. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Covestor Ltd grew its stake in Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC grew its stake in Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after buying an additional 1,556 shares during the last quarter. Quarry LP purchased a new position in Evolent Health during the 2nd quarter worth $32,000. Canada Pension Plan Investment Board purchased a new stake in Evolent Health during the 2nd quarter valued at about $61,000. Finally, Quest Partners LLC purchased a new stake in Evolent Health during the 2nd quarter valued at about $87,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.